

# SS INNOVATIONS INTERNATIONAL, INC.

## **FORM 8-K** (Current report filing)

Filed 06/30/26 for the Period Ending 06/30/26

|             |   |
|-------------|---|
| Telephone   | (954) 478-1410  |
| CIK         | 0001676163  |
| Symbol      | SSII  |
| SIC Code    | 3841 - Surgical and Medical Instruments and Apparatus |
| Industry    | Biotechnology & Medical Research                      |
| Sector      | Healthcare  |
| Fiscal Year | 12/31   |

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **June 30, 2026**

**SS INNOVATIONS INTERNATIONAL, INC.**  
(Exact name of registrant as specified in its charter)

**Florida**  
(State or Other Jurisdiction  
of Incorporation)

**001-42615**  
(Commission File Number)

**47-3478854**  
(IRS Employer  
Identification No.)

**405, 3rd Floor, iLabs Info Technology Centre  
Udyog Vihar, Phase III  
Gurugram, Haryana India**

(Address of Principal Executive Offices)

**122016**  
(Zip Code)

Registrant's telephone number, including area code: **+91 73375 53469**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each Class | Trading Symbol | Name of each exchange on which registered |
|---------------------|----------------|---|
| Common Stock        | SSII           | The Nasdaq Stock Market LLC               |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

As used in this Current Report on Form 8-K (this “**Current Report**”), the terms “**SSi**,” “**the Company**,” “**we**,” “**us**” and “**our**” refer to SS Innovations International, Inc. and its subsidiaries.

**Item 8.01 Other Events.**

On June 30, 2026, SSi issued a press release announcing the Company was named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards (“SRIA”).

A copy of the press release is included as **Exhibit 99.1** to this Current Report.

**Item 9.01 Financial Statements and Exhibits.**

(d) *Exhibits*

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 99.1               | <a href="#">Press Release, dated June 30, 2026</a>                          |
| 104                | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 30, 2026

**SS INNOVATIONS INTERNATIONAL, INC.**

By: /s/ Sudhir Srivastava

Sudhir Srivastava, M.D.

Chairman and Chief Executive Officer



**SS Innovations Named Outstanding Company Winner at the 2026 Surgical Robotics Industry Awards**  
*Company celebrated for advancing global access to its innovative robotic surgery platform*

**Fort Lauderdale, FL – June 30, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII)**, a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company was named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards (“SRIA”).

Each year, in the Outstanding Company category, SRIA recognizes a single winning surgical robotics company that demonstrates one or more of the following characteristics:

- an outstanding business or commercial success;
- a highly novel and/or inventive product, process, service, technology or procedure;
- policies, processes, products or services with a positive environmental or societal impact;
- recognition as an industry leading company by customers or the public;
- a positive stance on ethics/values; and
- standing as an excellent employer of choice.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We are delighted and honored to be named the Outstanding Company winner at this year’s prestigious Surgical Robotics Industry Awards. SS Innovations surpassed nine other well-established finalists to win this coveted industry accolade, which reflects our commitment to advancing surgical robotic technologies and democratizing global access to expert surgical care. We believe that surgeons and hospitals are embracing the SSi Mantra surgical robotic system due to its cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency.”

To learn more about the Surgical Robotics Industry Awards visit: [www.surgicalroboticsindustryawards.com](http://www.surgicalroboticsindustryawards.com).

As of June 22, 2026, the cumulative number of multi-specialty procedures completed with the SSi Mantra surgical robotic system totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.

To date, the SSi Mantra has been granted regulatory approval in 14 countries, including:

- Colombia
- Ecuador
- Guatemala
- Guyana
- India
- Indonesia
- Iraq
- Kenya
- Nepal
- Oman
- Philippines
- Sri Lanka
- Ukraine
- United Arab Emirates

**About SS Innovations**

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at [ssinnovations.com](http://ssinnovations.com) or LinkedIn for more information and updates.

## **About the SSi Mantra**

The SSi Mantra is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantraAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra's standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

## **Forward Looking Statements**

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "anticipate," "assume," "believe," "estimate," "expect," "will," "intend," "may," "plan," "project," "should," "could," "seek," "designed," "potential," "forecast," "target," "objective," "goal," or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations' future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

## **Investor Contact:**

The Equity Group  
Kalle Ahl, CFA  
T: (303) 953-9878  
kalle.ahl@theequitygroup.com

Devin Sullivan, Managing Director  
T: (212) 836-9608  
devin.sullivan@theequitygroup.com

## **Media Contact:**

RooneyPartners LLC  
Kate Barrette  
T: (212) 223-0561  
kbarrette@rooneypartners.com

---